Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma

被引：6
|
作者：
Maruyama, Dai [1 ]
Nagai, Hirokazu [2 ]
Fukuhara, Noriko [3 ]
Kitano, Toshiyuki [4 ]
Ishikawa, Takayuki [5 ]
Nishikawa, Tomoaki [6 ]
机构：
[1] Natl Canc Ctr, Dept Hematol, Tokyo, Japan
[2] Natl Hosp Org Nagoya Med Ctr, Dept Hematol, Nagoya, Aichi, Japan
[3] Tohoku Univ, Grad Sch Med, Dept Hematol & Rheumatol, Sendai, Miyagi, Japan
[4] Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Kyoto, Japan
[5] Kobe City Med Ctr Gen Hosp, Dept Hematol, Kobe, Hyogo, Japan
[6] Janssen Pharmaceut KK, Tokyo, Japan
来源：
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY | 2019年 / 59卷 / 02期
关键词：
covalent BTK inhibitor; ibrutinib; Japanese patients; mantle cell lymphoma; phase II clinical trial;
D O I：
10.3960/jslrt.19006
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：98 / 100
页数：3
相关论文
共 50 条
  • [1] Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
    Goto, Hideki
    Ito, Satoshi
    Kizaki, Masahiro
    Yamaguchi, Masaki
    Fukuhara, Noriko
    Kato, Koji
    Saito, Toko
    Terui, Yasuhito
    Okubo, Sumiko
    Soshin, Tomomi
    Zeng, Jiewei
    Honda, Hideyuki
    Badawi, Mohamed
    Ross, Jeremy A.
    Izutsu, Koji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (02) : 232 - 240
  • [2] Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
    Izutsu, Koji
    Goto, Hideki
    Kizaki, Masahiro
    Yamaguchi, Masaki
    Fukuhara, Noriko
    Kato, Koji
    Saito, Toko
    Terui, Yasuhito
    Okubo, Sumiko
    Soshin, Tomomi
    Mukherjee, Nabanita
    Honda, Hideyuki
    Badawi, Mohamed
    Ross, Jeremy
    Ishizawa, Kenichi
    ANNALS OF ONCOLOGY, 2023, 34 : S1428 - S1428
  • [3] Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
    Hideki Goto
    Satoshi Ito
    Masahiro Kizaki
    Masaki Yamaguchi
    Noriko Fukuhara
    Koji Kato
    Toko Saito
    Yasuhito Terui
    Sumiko Okubo
    Tomomi Soshin
    Jiewei Zeng
    Hideyuki Honda
    Mohamed Badawi
    Jeremy A. Ross
    Koji Izutsu
    International Journal of Clinical Oncology, 2024, 29 : 232 - 240
  • [4] Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
    Maruyama, Dai
    Nagai, Hirokazu
    Fukuhara, Noriko
    Kitano, Toshiyuki
    Ishikawa, Takayuki
    Shibayama, Hirohiko
    Choi, Ilseung
    Hatake, Kiyohiko
    Uchida, Toshiki
    Nishikori, Momoko
    Kinoshita, Tomohiro
    Matsuno, Yoshihiro
    Nishikawa, Tomoaki
    Takahara, Satoko
    Tobinai, Kensei
    CANCER SCIENCE, 2016, 107 (12) : 1785 - 1790
  • [5] Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study
    Tobinai, Kensei
    Uchida, Toshiki
    Fukuhara, Noriko
    Nishikawa, Tomoaki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (03) : 366 - 368
  • [6] Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study
    Kensei Tobinai
    Toshiki Uchida
    Noriko Fukuhara
    Tomoaki Nishikawa
    International Journal of Hematology, 2019, 109 : 366 - 368
  • [7] A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma
    Lee, Hun J.
    Schmelz, Jacob L.
    Cramer, Fred
    Romaguera, Jorge E.
    Badillo, Maria
    Wang, Michael
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (06) : E94 - E98
  • [8] A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404
    Cohen, Jonathon B.
    Portell, Craig A.
    Hamadani, Mehdi
    Jegede, Opeyemi
    Diefenbach, Catherine
    David, Kevin A.
    Fletcher, Christopher D.
    Landsburg, Daniel J.
    Kahl, Brad S.
    BLOOD, 2019, 134
  • [9] A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma
    Lee, Yong-Pyo
    Jung, Ye Ji
    Cho, Junhun
    Ko, Young Hyeh
    Kim, Won Seog
    Kim, Seok Jin
    Yoon, Sang Eun
    BLOOD RESEARCH, 2023, 58 (04) : 208 - 220
  • [10] Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
    Fisher, Richard I.
    Bernstein, Steven H.
    Kahl, Brad S.
    Djulbegovic, Benjamin
    Robertson, Michael J.
    de Vos, Sven
    Epner, Elliot
    Krishnan, Amrita
    Leonard, John P.
    Lonial, Sagar
    Stadtmauer, Edward A.
    O'Connor, Owen A.
    Shi, Hongliang
    Boral, Anthony L.
    Goy, Andre
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) : 4867 - 4874
12345